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Abstract
Background: Osteosarcoma (OSA) is a common malignant bone tumor of large breed dogs that occurs at predictable
anatomic sites. At the time of initial diagnosis, most affected dogs have occult pulmonary metastases. Even with
aggressive surgical treatment combined with chemotherapy, the majority of dogs diagnosed with OSA live less than
1 year from the time of diagnosis. The ability to identify canine OSA cases most responsive to treatment is needed.
In humans, OSA is also an aggressive tumor that is histologically and molecularly similar to canine OSA. The expression of
the tumor suppressor gene product P16 by human OSA tissue has been linked to a favorable response to chemotherapy.
Results: We identified an antibody that binds canine P16 and developed a canine OSA tissue microarray in order to test
the hypothesis that P16 expression by canine OSA tissue is predictive of clinical outcome following amputation and
chemotherapy. Although statistical significance was not reached, a trend was identified between the lack of canine OSA
P16 expression and a shorter disease free interval.
Conclusions: The identification of a molecular marker for canine OSA is an important goal and the results reported here
justify a larger study.
Keywords: Canine, Osteosarcoma, P16, Immunohistochemistry, Tissue microarray
Background
Canine osteosarcoma (OSA) is an aggressive and highly
metastatic tumor of bone and although it can occur at
any age and in any dog breed, it is most often diagnosed
in adult to older large to giant breed dogs. OSA is the
most common canine skeletal tumor, accounting for
approximately 80–85% of all bone tumors in dogs [1–3]
and tends to occur at the most active metaphyseal
regions of the appendicular skeleton. Relative to other
skeletal sarcomas, canine osteosarcoma pursues a
more rapid clinical course with earlier lung metastasis
than either chondrosarcoma or fibrosarcoma of bone
[4]. Early metastatic spread to the lungs contributes
to the poor overall prognosis for canine OSA. Human
OSA is histologically and molecularly similar to
canine OSA [5–7] and both can be difficult to
manage clinically [8, 9].
The current treatment of choice for canine OSA is
surgical excision (involving limb amputation or limb-
salvage surgery) followed by adjuvant platinum-based
chemotherapy. Stereotactic radiation therapy has been
reported as an alternative means to achieve local control
[10, 11]. The survival time of canine appendicular OSA
with adequate local control and without adjuvant
chemotherapy is 119–175 days with a 12 month survival
rate of only 11–21% [12]. In addition to surgery,
platinum-based chemotherapy alone or in combination
with doxorubicin has been shown to improve survival
time [13]. A large study involving 470 dogs identified no
difference in outcome between dogs with appendicular
osteosarcoma treated with carboplatin vs. alternating
carboplatin and doxorubicin [14]. Radiation therapy,
bisphosphonates, and analgesics such as non-steroidal
anti-inflammatory drugs and opioids can be utilized for
palliative therapies. Reflecting owner choices, the use of
palliative therapies alone generally result in relatively
short survival times [12].
In an attempt to predict biological behavior, canine
OSA has been categorized into a number of different
histologic subtypes. Some studies have indicated that
canine OSA histologic subtyping is not predictive of
biological outcome [15] while others have indicated
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that specific OSA subtypes, such as telangiectatic or
fibroblastic, may have negative or positive prognostic
implications, respectively [2, 16]. Histological classifi-
cations have been frequently shown to be less inform-
ative than molecular phenotypes when applied to
therapeutic outcome across a wide range of cancer
types. A molecular biomarker that is predictive of
canine OSA disease progression may assist prognostic
determinations and treatment decisions.
Expression of the tumor suppressor gene product
P16 by tumor tissue has recently been shown to sig-
nificantly correlate with chemotherapeutic response in
human osteosarcoma [9] and loss of P16 expression
by OSA cells has been associated with decreased
survival time in human patients with OSA [17–20].
Inactivation of tumor suppressor gene products like
P16 is an important event in oncogenesis that may
contribute to the development of canine OSA.
Therefore, P16 expression has the potential to be a
predictive signature of canine OSA tumor biology.
The tumor suppressor gene product P16 belongs to a
family of cyclin-dependent kinase inhibitors. When
bound to their respective cyclin dependent kinase, these
proteins increase the inhibitory effects of the retinoblast-
oma tumor suppressor gene at the G1-S checkpoint, a
‘point of no return’ for cell division [21, 22]. In a nor-
mally regulated cell, growth-inhibiting signals result in
P16 expression, blocking DNA synthesis and cell cycle
progression [23]. Deletion or mutational inactivation of
P16 can defeat the protective effect of the G1-S check-
point, potentially leading to unregulated cellular division
in a genetically damaged cell. Four of 6 previously
reported canine OSA cell lines have been shown to have
undetectable P16 protein or mRNA expression [23] and
numerous human cancers are associated with P16 gene
mutations, including osteosarcoma [21, 23].
We hypothesized that the presence or absence of P16
expression by canine OSA tissue is predictive of clinical
outcome. In order to test this hypothesis, the identifica-
tion of a P16 antibody that reliably binds canine P16 pro-
tein in immunoblot and immunohistochemistry (IHC)
assays was needed. Utilizing a set of control human and
canine tissues with known P16 expression patterns [24],
we identified an anti-P16 antibody with appropriate bind-
ing affinity in both immunoblot and IHC assays. In
addition, we developed a set of canine tissue microarrays
comprised of retrospective case material from 33 dogs
with appendicular OSA with known treatment regimens
and long-term outcomes.
Methods
Pathology and clinical features
In this retrospective study, 33 excisional biopsies (amputa-
tions) diagnosed as canine appendicular OSA were utilized
from patients enrolled in a randomized prospective study
comparing the adjuvant use of single-agent carboplatin or
alternating carboplatin and doxorubicin [13]. The inclusion
criteria for the current study were the availability of
sufficient high quality, formalin fixed, paraffin embedded
tumor tissue and known treatment and clinical outcome
data. Representative bone and soft tissue biopsy samples
had been previously sectioned and fixed in 10% buffered
formalin for a minimum of 48 h. Mineralized tissue was
thinly sectioned and decalcified in 15% formic acid for 2–
4 days, as needed. Tissue samples were routinely processed,
cut into 4 μm thick sections, placed on positively charged
glass slides and stained with hematoxylin and eosin accord-
ing to routine protocols. All specimens were confirmed to
be consistent with the diagnosis of osteosarcoma by a single
pathologist (MYM) based upon published criteria [2].
Canine OSA tumors were subclassified as osteoblastic,
chondroblastic, fibroblastic or mixed subtypes based upon
published criteria [2].
Tissue microarray
For each paraffin embedded tumor, optimal sites of
the formalin-fixed paraffin embedded blocks for core
sampling were identified. Characteristics of optimal
sites included the following features: high cellularity,
minimal necrosis, minimal hemorrhage and minimal
matrix or bone deposition. The construction of the
tissue microarray (TMA) was based upon a 2009
review by Parsons and Grabsh [25]. An Advanced
Tissue Arrayer (model ATA-100, Chemicon
International) was used to cut and insert canine OSA
tissue core samples, in triplicate, into pre-cast paraffin
blocks (Paraplast Plus, Sigma Aldrich). For the 33
canine cases, four canine OSA TMAs were con-
structed using a 9 × 6 grid pattern. Three, 2 mm
diameter core biopsies from each donor tissue block,
along with 2 positive control core biopsies (canine
glioblastoma tissue) were semi-randomly arranged in
the paraffin block while the outer circumferential
border was generally comprised of negative control
tissue (normal canine cerebrum or renal cortical tissue).
To generate unstained paraffin sections, each assembled
TMA was cut into 4 μm thick sections with a microtome
and placed on positively charged glass slides. TMA sec-
tions were stained with either hematoxylin and eosin
stains according to standard protocols or were further
processed for P16 immunohistochemistry.
Immunohistochemistry for P16
Immunohistochemistry (IHC) assays were performed on
whole sections of the positive control tissue (canine
glioblastoma), negative control tissue (normal canine
brain tissue and canine renal cortical tissue) and the con-
structed tissue microarrays. IHC assays were performed
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on 4 μm thick, formalin-fixed, paraffin-embedded tissue
sections, mounted on charged slides, and air-dried over-
night at 37o C. In order to ensure reproducible and homo-
geneous results between the IHC assays, a consistent
development time and protocol was utilized.
Sections were deparaffinized through xylene to reagent
alcohol, and treated with 0.3% hydrogen peroxide in
methanol for 30 min. Sections were then rehydrated to
water through graded reagent alcohols, and stabilized in
0.1 M Phosphate Buffered Saline, pH 7.4 (PBS). Antigen
retrieval required exposure of sections to Dako Target
Retrieval Solution, pH 9 (Dako, S2368) at 95o C for 30 min,
followed by a 20 min cool down at room temperature.
Sections were blocked for 20 min in 10% normal horse
serum in PBS. The primary antibody, a rabbit anti-P16 (SC-
373695, F-8, Santa Cruz Biotechnology) diluted 1:100 in
PBS-Tween 20 (0.02%) was applied for 1 h. All reagent in-
cubations were at room temperature, and PBS-Tween 20
rinses occurred twice between reagent applications for 3
min each change. Envision + System-HRP (Dako, K4003)
was applied for 30 min to label bound rabbit anti-P16
antibodies. The label was visualized with NovaRed for per-
oxidase (Vector, SK-4800). Sections were counterstained in
Mayer’s Hematoxylin, air-dried and coverslipped. Non-
specific background was evaluated with a duplicate section
receiving diluent in place of the primary antibody.
The sub-cellular location of the P16 antigen was
determined microscopically as nuclear, cytoplasmic or
membranous. To determine the level of P16 expression,
a semiquantitative scoring system was used based upon
the percent of neoplastic cells expressing P16 in a 100×
field of magnification: negative (0%), 1+ (<25%), 2+ (26–
79%), 3+ (80–100%) (at 100× magnification the entire
TMA biopsy section filled the field of view). The inten-
sity of P16 staining was not scored. The semiquantitative
ordinal scoring system was developed in accordance
with recommended histopathologic principles [26]. For
each canine OSA lesion on the TMA, one, two or three
tissue biopsies were examined and scored for P16
expression, as described above (Table 1). For each case,
a consensus P16 staining pattern was determined (1 of
1, 2 of 2, 2 of 3, or 3 of 3 sections). Discordant cases (1
of 2 sections) were re-reviewed by two anatomic pathol-
ogists (MYM and BGM) until a consensus could be
reached. All IHC sections were examined in a blinded
fashion where the pathologists were not aware of case
signalment, diagnosis or outcome.
Immunoblot
Control human and canine tissues were obtained from
cell culture, surgical biopsy or necropsy as previously
described [24]. Tissues know to express P16 (positive
controls) included the SAOS2 human osteosarcoma cell
line, a canine high grade oligodendroglioma (O8) and a
canine grade IV astrocytoma/glioblastoma (GBM, G2);
canine tissues previously demonstrated to not express
P16 (negative controls) included a different canine GBM
(G4), a high grade oligodendroglioma (O5) and normal
canine cerebrum (NB) [24].
Briefly, cells and tumor samples were lysed in radioim-
munoprecipitation assay buffer (RIPA) lysis buffer (Boston
BioProducts, Worcester, MA, USA) with 1X Halt protease
and phosphatase inhibitors (Thermo Fisher Scientific,
Rockford, IL, USA) and kept on ice or stored at −80 C if
not used immediately. Cell lysates were electrophoresed in
4–20% SDS Precast Polyacrylamide Gels (Expedeon) at
150 V for 45 min. The lysates were transferred overnight
onto a PVDF membrane (BioRad) at 50 V in a 5 C cold
room (PAGEgel Dual Run & Blot Vertical Mini-Gel
System). The PVDF membrane was washed three times in
tris-buffered saline with 0.1% Tween-20 (TBST), blocked
for 1 h with 5% nonfat milk/TBST (blocking buffer), and
subsequently washed 3 more times with TBST. The PVDF
membrane was then incubated overnight at 5C with
mouse monoclonal anti-P16 (1:500, SC-373695, F-8, Santa
Cruz Biotechnology) diluted in blocking buffer.
Membranes were then washed 3× and incubated with
HRP conjugated-goat anti-mouse IgG antibody (Santa
Cruz Biotechnology, IgG-HRP sc-2005) for 1 h at room
temperature. Finally, membranes were washed 3×, incu-
bated for 1 min with Pierce ECL reagent (Thermo Fisher
Scientific, Catalog number 32106) and imaged using a
FluorChem E digital imaging system (ProteinSimple).
Analysis and statistics
Disease free interval (DFI) and survival were defined as
described in Skorupski et al. [13]. The Kaplan-Meier
method was used to estimate DFI and survival and the
log-rank test was used to compare DFI and survival
times between P16 expression groups. Statistical analyses
were performed using commercial software (GraphPad
Prism version 6.0f ) and a p-value of <0.05 was consid-
ered significant. To determine if the decalcification
process interfered with P16 detection, the putative
correlation between P16 expression and decalcification
was determined using Fisher’s exact test.
Results
Pathology and clinical features
The anatomic locations of the canine OSA tumors, in
general, followed a predictable pattern reflecting the
most active growth plates of the appendicular skeleton.
There were two exceptions to this rule, in case 2, the
OSA lesion was identified in the proximal radius while
in case 6, the tumor was identified in the ulnar diaphysis
(Table 1). Consistent with the tendency of OSA to occur
in larger dogs, most of the dogs were large to giant
breeds. Approximately equal numbers of patients
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received each chemotherapeutic protocol. The majority
of the tumors were of the osteoblastic subtype (n = 27),
with fewer numbers of chondroblastic (n = 4) and one
case each of fibroblastic and mixed subtypes. Sections of
the tissue microarrays stained with hematoxylin and
eosin demonstrated histologically recognizable canine
positive control (GBM), canine negative control (normal
renal cortical or brain tissue) and canine osteosarcoma
tissues (Figs. 2 and 3).
Immunoblot
Immunoblot assay with the primary anti-P16 antibody (F-8)
revealed the presence of a 15-16 kDa band representing the
P16 protein in the SAOS-2 human cell line (lane 1), a ca-
nine high grade oligodendroglioma (08, lane 2) and a canine
GBM (G2, lane 3) (Fig. 1). No evidence of P16 protein
expression was observed in negative control lanes 4–6
representing a different canine GBM (G4), a canine high
grade oligodendroglioma (O5), and normal canine cerebrum
Table 1 Clinical and pathologic data for canine appendicular osteosarcomas
case De/NDe tx sex breed tumor location subtype # sct p16 exp
1 De C/D MC Mix Proximal tibia C 2 1+
2 De C/D FS GSD Proximal radius O 3 3+
3 NDe C MC Lab Proximal humerus O 3 3+
4 NDe C FS Grt Dane Distal radius C 3 2+
5 NDe C FS Rott Proximal tibia O 3 neg
6 NDe C MC Gold Ulnar diaphysis O 3 1+
7 De C/D MC Mix Distal radius O 3 3+
8 De C/D FS St. Bern Distal tibia O 3 3+
9 Nde C FS Gold Distal femur O 3 2+
10 De C FS Rott Distal femur O 3 3+
11 De C MC Rott Distal tibia O 3 neg
12 NDe C/D FS G Pyr Distal tibia O 3 2+
13 De C/D MC Bernese MD Distal radius O 2 neg
14 NDe C FS Rott Distal radius O 3 neg
15 De C FS Mix Distal femur O 3 3+
16 NDe C FS OESD Distal radius O 1 3+
17 NDe C/D FS Curly C Ret Proximal humerus O 3 3+
18 De C/D FS Rott Proximal tibia O 1 1+
19 De C/D FS Mix Distal radius O 3 3+
20 NDe C FS Lab Proximal humerus O 3 3+
21 NDe C/D MC Grey Prox humerus O 1 2+
22 NDe C/D MC Mix Distal radius F 3 2+
23 Nde C/D FS GSD Distal tibia O 3 3+
24 Nde C/D FS Malam Distal radius O 3 3+
25 De C/D FS Rott Distal femur O 3 neg
26 De C MC Mix Proximal humerus O 3 3+
27 NDe C/D FS Mix Distal tibia O 3 neg
28 De C/D MC Bernese MD Distal femur C 3 1+
29 De C FS Leonberger Distal radius O 3 1+
30 De C/D MC Ana Shep Distal radius O 2 2+
31 De C FS Lab Distal femur O 3 2+
32 De C MC GS Pointer Proximal humerus C 3 2+
33 De C M Rhod Rback Distal radius M 3 1+
Abbreviations: De- decalcified section, NDe- non-decalcified section, tx- treatment, C- carboplatin, D- doxorubicin, MC- male castrated, FS- female spayed, GSD-
German Shepherd dog, Lab- Labrador Retriever, Grt Dane- Great Dane, Rott- Rottweiler, Gold- Golden Retriever, St. Bern- Saint Bernard, G Pyr- Great Pyrenees,
Bernese MD- Bernese Mountain dog, OESD- Old English Sheep dog, Curly C Ret- Curly Coat Retriever, Grey- Greyhound, Malam- Malamute, Ana Shep- Anatolian
Shepherd, GS Pointer- German Shorthair Pointer, Rod Rback- Rhodesian Ridgeback, C- chondroblastic OSA, O- osteoblastic OSA, F- fibroblastic OSA, M- Mixed type
OSA, # sct- number of P16 IHC sections examined
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(NB). These results were consistent with previous results
using a different P16 antibody [24].
Immunohistochemistry
Using the same P16 antibody (F-8) as used in the immun-
noblot assay, P16 immunoreactivity was noted within the
cytoplasm and nuclei of the neoplastic cells comprising
the canine GBM (G2, positive expression control) but was
absent in normal canine cerebrum and canine renal cor-
tical tissue (negative expression controls) (Figs. 2 and 3).
Hence, an antibody capable of identifying the expression
of P16 in IHC assays was identified.
OSA biopsy tissues in the TMA were assigned an
ordinal value based upon the percent of neoplastic
cells expressing P16 in a 100× magnification field:
negative (0% cells), 1+ (<25% cells), 2+ (26–79%
cells), 3+ (80–100% cells). In the majority of cases,
three biopsy cores were examined and scored (n = 26
cases). In the remaining 6 cases, less than 3 biopsy
cores were available for scoring as a result of loss
during sectioning of the TMA blocks. In 3 cases, two
biopsy cores were examined, and in 3 cases, a single
core was examined and scored (Table 1). Although
decalcification had no significant effect on the immu-
nohistochemical scoring for P16 expression (p = 1.0)
(Table 1), the effect of treatment or lack of treatment
with decalcifying agents was not assessed within the
same sample.
Survival
Dogs with negative P16 immunoreactivity had a me-
dian disease free interval (DFI) of 125 days com-
pared to 201 days for dogs with any evidence of P16
immunoreactivity (1+, 2+ or 3+ P16 immunoreactiv-
ity, Fig. 4). This difference approached statistical
significance with a p value 0.055. Dogs with negative
P16 immunoreactivity had a median survival time of
179 days compared to 353 days for dogs with any
Fig. 1 P16 antibody (F-8) binds human and canine P16 protein in a
immunoblot assay. An appropriate size band (~15–16 kDa) is present
in protein lysates derived from cells or tissues known to express P16
(lane 1- human osteosarcoma SAOS2; lane 2-high grade canine
oligodendroglioma 08; lane 3- canine GBM G2). No bands are present
in protein lysates derived from tissues known to not express P16 (lane
4 canine GBM G4; lane 5- canine oligodendroglioma; lane 6- normal
canine brain NB)
a
b
Fig. 2 The organization and appearance of slides derived from canine OSA TMA stained with H&E stains or anti-P16 antibody (IHC). The TMA are
arranged in 9 columns (1–9) by 6 rows (A-F) comprising a 9 × 6 grid. The majority of 2 mm diameter biopsy cores are present in hematoxylin &
eosin-stained slides (TMA4) (a) and anti-P16 IHC (TMA3) (b). The outer row (columns 1 and 9, rows A and F) are generally comprised of negative
control tissue (canine renal cortical or brain tissue). Triplicate canine OSA biopsy (test) samples are located within the boxed regions and are
identified by case numbers (b). The location of positive control samples (GBM) are indicated (+) (b)
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P16 immunoreactivity. This difference was not sig-
nificant (p = 0.2). A comparison of samples with
strong p16 immunoreactivity (+2 or +3) versus nega-
tive immunoreactivity was performed and found to
be not significant (p = 0.09 for DFI and 0.3 for sur-
vival, respectively; data not shown).
Fourteen dogs treated with a combined chemother-
apy regimen (carboplatin and doxorubicin) demon-
strated at least some P16 expression while 3 dogs
treated with a combined therapy lacked P16 expres-
sion. 13 dogs treated with carboplatin alone had P16
expression while 3 dogs treated with carboplatin
alone lacked P16 expression (Table 1). As a result,
P16 expression did not correlate with chemotherapy
protocol (p = 1.00).
Discussion
In this study, we identified an anti-P16 antibody that spe-
cifically labeled canine and human cells/tissues previously
a b
c d
e f
Fig. 3 Immunohistochemistry assays reveal the proportion of neoplastic cells expressing P16. Canine glioblastoma cells demonstrate abundant
red-brown staining in both the cytoplasm and nucleus (GBM, + control P16 IHC) (a). Normal canine brain tissue demonstrates an absence of
red-brown stained cells (NB, negative control P16 IHC) (b). In a canine OSA, a majority of the neoplastic cells demonstrate red-brown cytoplasmic
staining (3+ staining, case 19) (c). In a canine OSA, approximately 50% of the neoplastic cells demonstrate red-brown cytoplasmic staining
(2+ staining, case 9) (d). In canine OSA, less than 25% of the neoplastic cells demonstrate red-brown cytoplasmic staining (1+ staining, case 4) (e).
In canine OSA, none of the neoplastic cells demonstrate red-brown cytoplasmic staining (0+ staining, case 13). P16 immunohistochemistry,
original magnification 400×
Fig. 4 For dogs with OSA, the disease free interval (DFI) is shorter
for tumors expressing P16 relative to tumors without P16 expression.
The percent survival of dogs with OSA that exhibit any P16 staining
(+1, +2 or +3, dashed line) and dogs with OSA that lack P16 staining
(solid line) are plotted in this survival plot
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shown to express P16 protein in immunoblots and immu-
nohistochemistry assays (positive controls); and failed to
label cells and tissues known to not express P16 protein
(negative controls). The Santa Cruz F-8 antibody is di-
rected towards an epitope mapping between amino acids
4–31 at the N-terminus of human P16. Within this region,
there are 4 amino acid mismatches between the human
and canine P16 protein sequence (data not shown). This
difference between the human and canine P16 sequences
is apparently insufficient to abrogate antibody binding.
Using this antibody in IHC assays with a set of 4
canine OSA tissue microarrays demonstrated P16
expression varying from no expression (0% of the
neoplastic cells express P16), up to 3+ expression
(80–100% of the neoplastic cells express P16).
Although statistical significance was not reached, a
trend was identified between the lack of P16 expres-
sion (negative staining) and a shorter DFI. This find-
ing in canine OSA is intriguing as inactivation of
P16 expression by mutation, deletion, or promoter
hypermethylation has been associated with continu-
ous cell proliferation in human OSA [9] and loss of
P16 expression has been correlated with decreased
survival time in human OSA [17].
In all of the examined canine OSA biopsy sections,
P16 protein expression, when present, was determined
to be cytoplasmic. In the positive control tissue (ca-
nine GBM), P16 expression was identified in both the
nucleus and cytoplasm of the neoplastic cells.
Although the specificity and validity of cytoplasmic
localization of P16 observed in some tumors has been
questioned, P16 has been shown to be expressed in
the cytoplasm of a wide variety of cell types [27–29].
Studies have reported the localization of P16 protein
in both the nucleus and the cytoplasm in multiple
neoplasms.
Interestingly, four of the six dogs with no P16 ex-
pression were Rottweilers, while only two of the 27
dogs with some P16 expression were Rottweilers
(Table 1). This finding is intriguing as Rottweilers,
along with Greyhounds and Great Danes, have been
shown to have an increased risk of developing OSA
[30]. McNeill and co-workers found that relative to
other dog breeds, Rottweilers are more likely to have
an aggressive form of OSA with a higher likelihood of
brain metastasis [31]. However, the McNeil study did
not confirm that these differences were associated
with a worse outcome. Studies have demonstrated
an association between specific dog breeds, like
Rottweillers, and the distribution of genomic copy
number imbalances in canine appendicular osteosar-
coma [32]. Such results indicate that individual gen-
etic backgrounds, as defined by dog breed, influence
tumor karyotypes in cancers like OSA with extensive
genomic instability. Reconciling the findings reported
here with these previous studies will require a larger
population of animals.
This pilot study had several limitations. Due to
sporadic sectional loss in the TMA, three biopsy
cores were not available for examination for every
case. The concordance for IHC staining between tis-
sue arrays with triplicate cores per tumor and full
sections has been shown to be 96–98% [33]. In the
study described here, the majority of cases (n = 26)
had three examined biopsy cores. However, as a re-
sult of tissue loss in some of the TMA sections, only
two biopsy cores were examined for 3 cases, and a
single core was examined and scored for 3 cases.
The percent mismatch (nonconcordance) between
the immunohistochemical scoring of biopsy cores
and the full section has been determined to be 3.7,
4.4 and 9.4% for 3, 2 and 1 core, respectively [33].
Although the examination and scoring of less than 3
sections is considered suboptimal, a nonconcordance
rate of <10% was considered to be acceptable for
this pilot study.
Overall case numbers were low (n = 33), and the num-
ber of cases completely lacking P16 expression (n = 6)
was particularly low. This limitation might have re-
sulted in a type II error (“false negative”) in results
comparing P16 staining to overall outcome (DFI).
This possibility is suggested by the close p-value for
DFI and large difference in median survival despite a
non-significant p-value. In addition, dogs included in
the study received 2 different adjuvant chemotherapy
protocols and the study from which the cases were
collected showed a significant difference between
DFI in these protocols. Although we found no
association between P16 staining and chemotherapy
protocol, larger studies with uniform treatment
would be more ideal.
Conclusions
This study, demonstrating a trend between the lack of
P16 expression in canine appendicular OSA lesions
and a shorter DFI, provides preliminary data justifying
a larger study. The identification of a molecular
marker reliably indicating prognosis for canine appen-
dicular OSA is needed.
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